Andrea Cook, PhD, is a biostatistician whose work focuses on leveraging available data such as electronic health records (EHRs) to efficiently address important public health questions and improve the overall health of our population. Dr. Cook has developed research methods using EHRs and other existing health care data for major initiatives led by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA). Her work spans many areas, including hypertension control, cancer screening, obesity, diabetes, built environment, and alternative medicine for pain.
The goal of Dr. Cook’s research is finding interventions that improve patient care. She studies how pragmatic clinical trials, which are conducted under real-world conditions in health care organizations such as Kaiser Permanente Washington, can deliver more effective care and improve patient outcomes. Dr. Cook is a lead biostatistician for the Biostatistics and Study Design Core of the NIH Collaboratory, which facilitates the implementation of pragmatic clinical trials. She addresses the numerous statistical challenges of pragmatic clinical trials including how to design studies to answer research questions without impeding the delivery of care and how to use EHRs for more cost-effective studies.
Dr. Cook also studies how to use EHR data to improve the way we monitor the safety of new medical products including vaccines, drugs, and medical devices. She contributes to the FDA Sentinel Initiative and the CDC Vaccine Safety Datalink and has led the development of new statistical methods for actively monitoring medical products for rare adverse events using distributed data networks.
Dr. Cook obtained her PhD in biostatistics from the Harvard T.H. Chan School of Public Health in 2005. She is a member of the American Statistical Association and the Western North American Region of the International Biometric Society. She is also an affiliate professor in biostatistics at the University of Washington.
Role of built environment; obesity prevention and control; nutrition
Analysis of longitudinal data; sequential methods
Physical activity; nutrition; built environment
Wang X, Turner EL, Li F, Wang R, Moyer J, Cook AJ, Murray DM, Heagerty PJ. Two weights make a wrong: cluster randomized trials with variable cluster sizes and heterogeneous treatment effects. Contemp Clin Trials. 2022 Feb 2:106702. doi: 10.1016/j.cct.2022.106702. Online ahead of print. PubMed
Coughlin JW, Nauman E, Wellman R, Coley RY, McTigue KM, Coleman KJ, Jones DB, Lewis K, Tobin JN, Wee CC, Fitzpatrick SL, Desai JR, Murali S, Morrow EH, Rogers AM, Wood GC, Schlundt DG, Apovian CM, Duke MC, McClay JC, Soans R, Nemr R, Williams N, Courcoulas A, Holmes JH, Anau J, Toh S, Sturtevant JL, Horgan CE, Cook AJ, Arterburn DE; PCORnet Bariatric Study Collaborative. Preoperative depression status and five year metabolic and bariatric surgery outcomes in the PCORNET bariatric study cohort. Ann Surg. 2022 Jan 19. doi: 10.1097/SLA.0000000000005364. [Epub ahead of print]. PubMed
Rosenberg DE, Greenwood-Hickman MA, Zhou J, Cook AJ, Mettert KD, Cooper J, Arterburn D, Green BB, Walsh-Bailey C, Kerr J, Owen N, Dunstan D, McClure JB. Protocol for a randomized controlled trial of sitting reduction to improve cardiometabolic health in older adults. Contemp Clin Trials. 2021 Dec;111:106593. doi: 10.1016/j.cct.2021.106593. Epub 2021 Oct 16. PubMed
Buszkiewicz JH, Bobb JF, Kapos F, Hurvitz PM, Arterburn D, Moudon AV, Cook A, Mooney SJ, Cruz M, Gupta S, Lozano P, Rosenberg DE, Theis MK, Anau J, Drewnowski A. Differential associations of the built environment on weight gain by sex and race/ethnicity but not age. Int J Obes (Lond). 2021 Aug 27. doi: 10.1038/s41366-021-00937-9. [Epub ahead of print]. PubMed
A new study finds that moving from low- to high-density neighborhoods might be related to reductions in weight gain.
New research suggests fast food and other aspects of built environments don’t affect weight, contrary to earlier findings.
Dr. Jennifer Nelson explains how KP scientists are helping the CDC and FDA keep an eye out for rare adverse events.